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Abstract   Lysophosphatidic acid (LPA) and sphingoshine-1-phosphate (S1P) are 
bioactive lysophospholipids which affect various cellular processes through G 
protein-coupled receptors. In our current study, we found by in situ hybridization that 
E11.5 mouse embryos strongly expressed the LPA receptor subtype LPA1 in 
cartilaginous bone primordia and the surrounding mesenchymal cells. However, despite 
their wide-ranging actions, the roles of lysophospholipids in chondrogenesis remain 
poorly understood. The mouse clonal cell line ATDC5 undergoes a sequential 
differentiation of chondroprogenitor cells in vitro. Undifferentiated and differentiated 
ATDC5 cells express LPA1 and other lysophospholipid receptors including S1P receptor 
S1P1 and S1P2. Taking advantage of this cell model, we studied the effects of LPA on 
the activities of chondroprogenitor cells. LPA markedly stimulates both DNA synthesis 
and the migration of ATDC5 chondroprogenitor cells in culture, whereas S1P suppresses 
the migration of these cells. Treatment with Ki16425, an LPA1- and LPA3-specific 
receptor antagonist, suppressed the fetal bovine serum-stimulated migration of ATDC5 
cells by almost 80%. These results indicate that LPA plays an important role in the 
activation of chondroprogenitor cells.  
 
Key words: ATDC5 cells, lysophosphatidic acid, sphingoshine-1-phosphate, cell 
migration, chondroprogenitor cells  
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Introduction 
Endochondral bone formation begins with the migration and condensation of 
chondroprogenitor cells. Subsequent overt chondrogenesis provides a cartilaginous 
mold for bone formation in mammals [1-3]. It has been shown that autotaxin (ATX), a 
tumor cell motility-stimulating factor [4,5], is abundantly expressed in the condensing 
mesenchyme of the future vertebra and also in the epiphyseal region of the developing 
limb in mouse and chick embryos [6,7]. This suggests a physiological role of 
lysophosphatidic acid (LPA) at these sites during skeletal development, since ATX has 
been identified as a secreted lysophospholipase D and plays a principal role in LPA 
production in the body [8,9]. However, ATX null mice exhibit lethality at around E10.5 
as a result of severe defects in vascular development prior to skeletal development 
[10,11]. This lethal phenotype hampers the analysis of the roles of LPA signaling in 
chondrogenesis in vivo.  
The endothelial differentiation gene (Edg) family of G protein-coupled 
receptors (GPCRs) is a structurally related subfamily of the LPA and 
sphingoshine-1-phosphate (S1P) receptors, comprising three LPA receptors (LPA1-3) and 
five S1P receptors (S1P1-5), which are thought to transmit both distinct and overlapping 
signals [12-15]. The recently identified non-EDG family LPA receptors, LPA4/p2y9 [16], 
LPA5/GPR92 [17,18], LPA6/GPR87 [19], LPA7/p2y5 [20,21], and LPA8/p2y10 [22], are 
more closely related to the purinoreceptor gene cluster and share less than 20% amino 
acid identity with EDG-LPA receptors. Gene-targeting studies for EDG family LPA 
receptors have revealed roles for these signals in physiological processes: 
LPA1-deficient mice exhibit abnormal sucking behavior after birth and nearly 50% of 
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these animals die at this stage [23]. Surviving mice show defects in craniofacial 
development and have a short nose, indicating a role for LPA1 in both craniofacial and 
neural crest development. S1P1 signaling has also been suggested to function in limb 
development [24,25]. Kim and colleagues have reported that LPA stimulates cell 
migration and the proliferation of rat primary chondrocytes [26,27], whilst Facchini et 
al have shown that LPA inhibits the proliferation of immortalized human juvenile costal 
chondrocytes [28]. However, little is still known about the actions of LPA on 
chondroprogenitor cells. 
We have previously demonstrated that the mouse clonal cell line ATDC5 
retains the properties of chondroprogenitors [29,30]: Undifferentiated ATDC5 cells 
adopt a fibroblastic morphology in sparse cultures, and rapidly proliferate in the 
presence of 5% fetal bovine serum (FBS) to form a confluent monolayer and cease 
growth due to contact inhibition [29]. In the presence of 10 g/ml insulin, ATDC5 cells 
with an elongated spindle-like morphology appear to form areas of cellular 
condensation [29]. Subsequently, differentiated chondrocytes with a rounded 
morphology appear in the condensation areas and re-enter the growth state with a longer 
cell doubling time to form cartilage nodules. As cartilage nodules expand with the 
growth of chondrocytes and accumulation of cartilage matrix, cells in the depth of the 
cartilage nodules become hypertrophic with the expression of type X collagen [30]. In 
our current study, we report the effects of LPA on the behavior of ATDC5 
chondroprogenitor cells in vitro.  
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Materials and methods 
Materials 
LPA, pertussis toxin (PTX), Ki16425, sodium selenite, and fatty acid-free bovine serum 
albumin (BSA) were purchased from Sigma (St. Louis, MO). Human insulin, and 
human transferrin were obtained from Roche (Mannheim, Germany). DMEM/F12 and 
MEM were purchased from Mediatech Inc. (Herndon, VA) and Sigma (St. Louis, MO), 
respectively. S1P was obtained from BIOMOL (Plymouth Meeting, PA). Stock solutions 
of LPA and S1P were prepared in 1% BSA/PBS. Ki16425 was dissolved in dimethyl 
sulfoxide (DMSO) and added to the cell cultures at a 1000-fold dilution. LY294002 and 
Y-27632 were purchased from Calbiochem (LA Jolla, CA). U0126 was obtained from 
Cell Signaling Technology (Beverly, MA). Recombinant human fibroblast growth 
factor-2 (FGF-2), human platelet-derived growth factor-BB (PDGF-BB) and mouse 
insulin-like growth factor-I (IGF-I) were sourced from R&D Systems (Minneapolis, 
MN). Bromo-2’-deoxyuridine (BrdU) and BrdU labeling kit III were obtained from 
Roche (Mannheim, Germany). The phosphoPlus p44/42 MAP kinase (Thr202/Tyr204) 
antibody Kit was purchased from Cell Signaling (Danvers, MA). Anti-RhoA mouse 
monoclonal antibody and Rhotekin-RBD agarose beads were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA) and Millipore (Temecula, CA), respectively. 
Cell culture 
Undifferentiated ATDC5 chondroprogenitor cells were grown at the initial seeding 
density of 3 × 10
5
 cells in T75 flasks and maintained at a subconfluent or lower cell 
density in DMEM/F12 supplemented with 5% FBS and ITS (10 g/ml human insulin 
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(I), 10 g/ml human transferrin (T) and 3 × 10-8 M sodium selenite (S)) at 37˚C under 
5% CO2 in air [29,31]. Every third day, subconfluent cultures were trypsinized and a 
portion of the harvested cells were used in subsequent experiments: cells were plated at 
2 × 10
4
 cells/well in 24-multiwell plates, 4 × 10
4
 cells/well in 12-multiwell plates, or 6 
× 10
4
 cells/well in 6-multiwell plates in the same medium. Cultures reached confluence 
on day 3. On day 17, the culture medium was replaced with MEM containing 5% FBS 
and ITS under 3% CO2 to facilitate cellular hypertrophy and mineralization. 
DMEM/F12 containing Ki16425 was used in some experiments. The culture medium 
was replaced every other day.  
Northern blot hybridization 
ATDC5 cells were plated at 6 × 10
4
 cells/well in 6-multiwell plates and cultured for the 
appropriate number of days and tissues were dissected from 11 week-old (testis, lung, 
and kidney) or 3 week-old (rib cartilage) ICR male mice. Total RNA was extracted from 
cultured ATDC5 cells or from the dissected tissues using the single-step method [32], 
resolved on 1% agarose-formaldehyde gels, and transferred to Nytran membranes using 
Turboblotter (Schleicher and Schuell, Dassel, Germany). To prepare hybridization 
probes, first strand cDNA was synthesized with SuperScript II RNase H
-
 reverse 
transcriptase (Gibco BRL, Grand Island, NY), and RT-PCR was performed using the 
primer sets listed in Table 1. The amplified cDNA fragments were subcloned into the 
pCRII-TOPO vector (Invitrogen, Carlsbad, CA), sequenced, and then labeled with 
[-32P]dCTP (Amersham Biosciences, Piscataway, NJ) via the random-primer method 
with a BcaBEST labeling kit (Takara, Shiga, Japan). The cDNA fragments used for the 
synthesis of 1(II) collagen and 1(X) collagen probes were prepared from pKT1180 
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[33] and pSAm10h [34], respectively. Hybridization was performed overnight at 42˚C 
with an appropriate probe in a solution containing 50% formamide, 6 × SSPE, 0.1% 
BSA, 0.1% Ficoll 400, 0.1% polyvinylpyrrolidone, 0.5% SDS and 100 g/ml denatured 
salmon sperm DNA. The membranes were washed three times at 55˚C for 20 min in 
0.1% SDS, 0.1× SSPE and exposed to BioMax MS Film (Carestream Health, Rochester, 
NY) at -80˚C. A quantitative analysis of hybridization signals was performed by 
scanning densitometry of autoradiograph using Fuji Film Science Lab 99 Image Gauge 
ver. 3.4 software (Fuji Photo Film, Tokyo, Japan). 
In situ hybridization 
Antisense and sense (control) riboprobes for each gene were prepared using a 
digoxygenin (DIG) RNA labeling kit (Roche) using appropriate cDNA fragments. E11.5 
embryos of ICR mice were dissected from female mice, embedded in OCT compound 
(Sakura Finetek & Tissue-Tek, Tokyo, Japan). Sections of 12-m-thickness were 
mounted onto microscope slides, air-dried at 50˚C and fixed briefly with 4% 
paraformaldehyde. Hybridization was performed at 58˚C for 16 h with an appropriate 
probe in a solution containing 50% formamide, 5 × SSC and 40 g/ml salmon sperm 
DNA. Following washing under high stringency conditions, DIG-labeled molecules 
were visualized using BM purple (Roche) as the substrate for anti-DIG 
antibody-coupled alkaline phosphatase.  
DNA synthesis and cell proliferation assays 
ATDC5 cells were plated at 5 × 10
3
 cells/well in 96-multiwell plates, grown in 
DMEM/F12 containing 5% FBS and ITS for three days to confluence, and preincubated 
with DMEM/F12 containing 0.1% BSA with or without 100 ng/ml PTX for 24 h. The 
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cultures were then treated with various concentrations of different factors for 24 h. Cells 
were labeled with 1 nmol/ml BrdU for the last 4 h of this incubation. Incorporation of 
BrdU into DNA was determined using a BrdU labeling kit III (Roche) in accordance 
with the manufacturer’s instructions. Absorbances at 405 nm were measured with a 
Model 450 Microplate Reader (Bio-Rad, Hercules, CA).  
For the determination of growth response of confluent ATDC5 cells, the cells 
(4 × 10
4
 cells/well) were plated in 12-multiwell plates and grown to confluence in 
DMEM/F12 containing 5% FBS. The cells were preincubated with DMEM/F12 
containing 0.3% FBS for 24 h. The medium was then replaced by the same medium 
with test samples. After 36 h, the number of cells in each well was counted with a 
hemocytometer after trypsinization. 
Western blotting analysis of ERK1/2 phosphorylation 
Confluent ATDC5 cells were preincubated for 6 h in DMEM/F12 containing 0.1% BSA 
in 12-multiwell plates. In some experiments, the cells were preincubated with 100 ng/ml 
PTX for the last 4 h. The culture medium was then replaced by DMEM/F12 containing 
0.1% BSA, and the cells were incubated with various concentrations of LPA with or 
without Ki16425 for the indicated times. After incubation, the cells were immediately 
rinsed with PBS, and lysed with SDS sample buffer. The resultant cell lysates were 
boiled for 5 min and separated using 12% SDS-PAGE gels, and transferred onto 
nitrocellulose membrane (Bio-Rad, Hercules, CA). The membranes were preincubated 
with 3.2% skim milk in Tris buffered saline for 20 min and analyzed by a PhosphoPlus 
p44/42 MAP kinase (Thr202/Tyr204) antibody kit in accordance with the 
manufacturer’s instructions. 
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Cell migration assay 
The transwell migration of ATDC5 cells was determined using a modified Boyden 
chamber assay. Both sides of an 8-m-pore migration chamber (24-well format; Becton 
Dickinson, Franklin Lakes, NJ) were coated with 50 g/ml type I collagen at 4˚C 
overnight, air-dried and washed twice with PBS prior to plating the cells. The cells were 
harvested and washed twice with migration medium (DMEM/F12 containing 0.1% BSA 
and ITS). Cells (5 × 10
4
) suspended in 300 l of the migration medium were seeded in 
the top well of the chamber and allowed to migrate for 4 h at 37˚C under 5% CO2 in air 
toward the bottom well filled with 600 l of the migration medium containing various 
factors. In some experiments, ITS was omitted from the migration medium. Various 
concentrations of Ki16425 were added in the migration medium in the top well of the 
chamber in some assays. LY294002, U0126, and Y-27632 were added to both of the 
chambers and preincubated with cells for 30 min at 37˚C prior to seeding. The cells 
were fixed with 4% paraformaldehyde and stained with Dif Quick (Sysmex, Kobe, 
Japan). The non-migrated cells on the top well were removed with a cotton swab, and 
the migrated cells on the bottom of the chamber were photographed under a light 
microscope at a magnification of × 200 and counted in four randomly selected fields.  
LPA1 knockdown by RNA interference 
Small interfering RNA (siRNA) oligonucleotide duplexes were purchased from 
Dharmacon (Lafayette, CO). LPA1 were knocked down using a pool of four siRNA 
duplexes (siGENOME SMART pool, M-043497-01-0005) and siGENOME 
Non-Targeting siRNA Pool #1 (D-001206-13-05) was used for control experiment. 
Transfection of siRNA into ATDC5 cells was performed by electroporation using 
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Amaxa Nucleofector system (Amaxa, Gaithersburg, MD) according to the 
manufacture’s instructions. Briefly, subconfluent cells were harvested and 1×106 cells 
were resuspended in 100 l of Nucleofector solution T. LPA1 or non-targeting siRNA 
(100 pmol) was added to the cell suspension and cells were electroporated with program 
T-020. The cells were immediately resuspended in DMEM/F12 supplemented with 5% 
FBS and ITS, plated onto 6-multiwell plates. After 24 h, total RNA was extracted, 
reverse-transcribed using SuperScript II RNase H
-
 reverse transcriptase (Gibco BRL, 
Grand Island, NY). Efficiency of LPA1 knockdown was evaluated by RT-PCR analysis 
using primer sets listed in Table I. Amplification of 
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was utilized as an internal 
control and the primer sequences used were as follows: GAPDH forward primer: 
5’-ACCACAGTCCATGCCATCAC-3’; GAPDH reverse primer: 
5’-TCCACCACCCTGTTGCTGTA-3’. 
Immunofluorescence microscopy 
ATDC5 cells grown on Lab-Tek II glass CC2 chamber slides (Nalgen Nunc 
International, Naperville IL) were incubated for 6 h in DMEM/F12 containing 0.1% 
BSA, and stimulated with or without 100 nM LPA at 37˚C for the last 30 min in the 
presence or absence of 3 M Ki16425. The cells were then fixed with 4% 
paraformaldehyde for 10 min and permeabilized with 0.2% Triton X-100 for a further 4 
min. After blocking in 5% skim milk/PBS for 30 min, cells were incubated with 
anti-paxillin mouse IgG (BD transduction laboratories, San Jose, CA) at 4˚C overnight, 
followed by incubation for 1 h with a mixture of Alexa Fluor 594-conjugated phalloidin 
(Invitrogen), Alexa Fluor 488-conjugated anti mouse IgG (Invitrogen) and 1 g/ml 
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DAPI (Sigma). Coverslips were mounted on glass chamber slides using Prolong Gold 
(Invitrogen) and examined by fluorescence microscopy (Leica Microsystems, 
Mannheim, Germany). 
RhoA pull-down assay 
ATDC5 cells were plated at 5 × 10
5
 cells in 100-mm culture dishes, and grown to 
confluence. The confluent cultures were then preincubated in DMEM/F12 containing 
0.1% BSA for 6 h, stimulated with various concentrations of LPA for 2 min, 
immediately rinsed with ice-cold PBS, and then lysed with ice-cold lysis buffer 
containing 1% Igepal CA-630, 25 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 
10 mM MgCl2, 1 mM EDTA, 10 g/ml leupeptin, and 10 g/ml aprotinin. Lysates were 
incubated at 4˚C for 20 min and clarified by centrifugation. Aliquots of clarified lysates 
were then denatured in SDS sample buffer and used for the analysis of total RhoA levels. 
For pull-down assays, lysates were incubated with 25 g of Rhotekin-RBD agarose 
beads (Millipore, Temecula, CA) for 1 h at 4˚C. The beads were rinsed three times with 
the lysis buffer and bound proteins were eluted by boiling in 30 l of SDS sample buffer. 
Samples were separated in 12% SDS-PAGE and subjected to western blot analysis 
using a mouse monoclonal antibody against RhoA (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA). 
Alcian blue staining 
Cells were rinsed with PBS, fixed with 95% methanol for 20 minutes, air-dried and 
stained with 0.1% Alcian blue 8GS (Fluka, Buchs, Switzerland) in 0.1 M HCl overnight 
at room temperature. The stained wells were photographed and the Alcian blue positive 




Results and Discussion 
The lysophosphatidic acid receptor LPA1 is expressed in chondrogenic cells 
Since the LPA receptor subtype LPA1 has been shown to mediate the signals underlying 
LPA activities in many cell types [35], we studied the expression pattern of the 
lysophosphatidic acid receptor LPA1 at an early stage of skeletal development in mouse 
embryos at E10.5 and E11.5 by in situ hybridization (Figs. 1 and 2). LPA1 was 
expressed in the cartilaginous elements of vertebrae (Figs. 1A, C, and E, arrowheads) 
that expressed type II collagen, and diffusely expressed in the mesenchymal cells 
surrounding axial skeletal elements. The region of LPA1 expression was found to be 
overlapped with Sox9-positive prechondrogenic region (Fig. 1C, also expressed in 
neural tube) and also Pax1-positive sclerotome compartment (Fig. 1D, dotted circles) 
from which mesenchymal cells migrate to form vertebral body [36,37]. The intense 
expression of ATX was found in the floor plate of neural tube (Fig. 1F). Some regions 
surrounding the floor plate including LPA1-expressing prechondrogenic regions were 
also found to express ATX, although the detected hybridization signals were faint but 
clearly positive. Thus the ATX-positive LPA-production domains in embryos seem to 
localize within or close enough to the Sox9- or Pax1-positive prechondrogenic regions 
and cartilaginous primordia, which are also LPA1-positive. At E11.5, LPA1 transcripts 
were more clearly localized to the cartilaginous bone primordia of the vertebrae (Figs. 
2A and E), particularly in the posterior regions of the vertebrae that overlap with the 
expression domain of ATX [6,7]. In addition to these sites, LPA1 transcripts were 
evident in the medial nasal process, the mandibular compartment of first and second 
branchial arches, and other structures (Fig. 2A), implicating LPA1 signaling in 
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chondrogenesis during skeletal development. Expression of other LPA and S1P receptor 
subtypes was less evident. 
To further study the role of lysophospholipid in chondrogenesis in vitro, we 
examined the expression of some of the known lysophospholipid receptors, including 
LPA1-3 and S1P1-3, during chondrogenic differentiation in mouse ATDC5 cells. Northern 
blot analysis revealed that undifferentiated ATDC5 chondroprogenitor cells expressed 
transcripts for LPA and S1P receptors on day 3 (Fig. 3). Notably, the levels of LPA1 
transcripts were prominent compared with other known tissues that express this receptor 
subtype including the adult mouse testis and lung [38], and comparable to those in rib 
cartilage. The LPA1 levels were high in ATDC5 cells at the undifferentiated and 
condensation stage (days 3 and 7, respectively), and decreased with the progression of 
chondrogenic differentiation as characterized by the induction of type II collagen 
transcripts (days 14 and 17). The expression of LPA1 transcripts increased again during 
the hypertrophy/calcification stages (days 26 and 42) as characterized by an abundant 
expression of type X collagen transcripts. LPA2 transcripts were also detected, but LPA3 
was not evident (Fig. 3). Transcripts for all three S1P receptors (S1P1-3) were detected in 
undifferentiated ATDC5 chondroprogenitor cells (day 3). However, the cells mainly 
expressed S1P2 transcripts at a level comparable to that in mouse lung, which is known 
to express transcripts for all three S1P receptors (S1P1-3) [39]. No significant changes 
were observed in the levels of S1P1 or S1P2 transcripts during differentiation. These 
results indicate the possibility that ATDC5 cells can respond to lysophospholipids 
through their cognate receptors. Among others, LPA1 may play a role in 
chondrogenesis. 
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LPA stimulates DNA synthesis in ATDC5 chondroprogenitor cells 
Quiescent cultures of undifferentiated ATDC5 cells were treated with LPA or S1P for 24 
h and the rate of DNA synthesis was assessed by BrdU incorporation during the last 4 h 
of the incubation period. LPA was found to stimulate DNA synthesis in ATDC5 cells in 
a dose-dependent manner (Fig. 4A). LPA (10 M) also increased BrdU incorporation by 
about 6-fold compared with the control, whereas S1P had little effect (Fig. 4B). The 
stimulatory effects of LPA were blocked when the cells were pretreated with the 
Gi-specific inhibitor PTX, indicating that the effects of LPA are GPCR-mediated. For 
comparison, the same cells were treated with FGF-2 (1 ng/ml) as a positive control for 
growth stimulation and BrdU incorporation was increased by about 10-fold (955 ± 45% 
and 978 ± 100% of control in the absence and presence of 100 ng/ml PTX, respectively). 
In agreement with an increase in DNA synthesis, a 1 ng/ml concentration of FGF-2 
increased the cell number in confluent cultures of ATDC5 cells by about 1.8-fold over 
the control (Fig. 4C). In comparison, 10 M LPA moderately stimulated proliferation of 
cells and the cell number increased by 1.3-fold (Fig. 4C). Hence, we next examined the 
activation of a MAPK pathway.  
In quiescent ATDC5 cells in confluent culture, LPA (0.1 M) appeared to 
stimulate the phosphorylation of ERK1/2 within 5 min, and phosphorylated ERK1/2 
(p-ERK1/2) was reduced to basal levels within 10 min (Fig. 4D). As shown in Figure 
4E, the levels of p-ERK1/2 were increased by the LPA treatment in a dose-dependent 
manner. This stimulation of ERK1/2 phosphorylation was abolished by PTX, suggesting 
that the Gi-ERK pathway plays a role in the LPA-induced activation of ATDC5 cells. 
The LPA-induced phosphorylation of ERK1/2 was also abrogated by the LPA receptor 
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antagonist Ki16425 (3 M) which preferentially blocks LPA1 and LPA3 signaling [40] 
(Fig. 4E).  
LPA markedly stimulates the migration of ATDC5 chondroprogenitor cells 
The effects of LPA and S1P upon the transwell migration of undifferentiated ATDC5 
cells were examined. S1P appeared to inhibit cell migration to below the control levels 
at 0.1-1 M, even though this effect was not statistically significant (Fig. 5A). In 
contrast, as shown in Figure 5A, LPA markedly stimulated migration and produces a 
bell-shaped dose-response curve. These stimulatory effects were evident at a 
concentration of only 0.001 M, reached maximal levels at around 0.1 M, and 
decreased to basal levels at 10 M. The stimulatory effects of LPA were completely 
abolished by PTX pretreatment of the cells (Fig. 5B), and attenuated in the presence of 
PI3K selective inhibitor (LY294002), but not MEK1/2 inhibitor (U0126) and Rho 
kinase inhibitor (Y-27632) (Fig. 5C). These experiments suggest that the Gi-PI3K 
signaling pathway plays a critical role in the stimulatory phase of a LPA effect on 
ATDC5 cells.  
As shown in Figure 5D, the LPA-induced migration of ATDC5 cells was 
suppressed by Ki16425 in a dose-dependent manner. Moreover, the stimulatory effects 
of 0.1 M LPA were almost completely abrogated by Ki16425 at a concentration of 1 
M or higher. The micromolar range of LPA has been reported to monotonically 
stimulate the migration of mesenchymal stem cells as well as primary chondrocytes 
[27,41]. Hence, the treatment of these cell-types with 10 M LPA results in a 
remarkable stimulation of migration. In contrast, ATDC5 cells showed almost no 
migratory activity in response to 10 M LPA. However, the migration of ATDC5 
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chondroprogenitor cells was markedly stimulated in response to a lower concentration 
of LPA (0.01-1 M) (Fig. 5A) [27,41]. In this respect, ATDC5 cells are sensitive to LPA 
upon migration. The bell-shaped dose-response profile appears to be characteristic of 
ATDC5 chondroprogenitor cells, suggesting that a unique mode of regulation may 
operate in the cells.  
Cell migration involves dynamic and spatial changes in cytoskeleton and cell 
adhesion. In contrast to the polygonal cells in the control culture (Fig. 5E, panel 1), 0.1 
M LPA was found to markedly induce the formation of actin stress fibers and focal 
adhesions with active lamellipodial extensions in ATDC5 cells (Fig. 5E, panel 2). This 
effect on the actin cytoskeletal reorganization was abolished by 3 M Ki16425 (Fig. 5E, 
panel 3). Cells treated with a higher dose of LPA (10 M) adopted a less-extended 
shape and appeared to be smaller in size and less motile (Fig. 5E, panel 4). In these 
cases, most of the lamellipodial extensions were retracted and actin stress fibers became 
less evident. It has been shown that the Rho GTPases play key roles in coordinating the 
cellular responses required for cell migration [42,43]. The driving force for migration is 
generated by the extension of lamellipodia, the formation of new adhesion sites at the 
migrating front, and cell body contraction with tail detachment of the adhesions. As 
suggested in previous studies [42,43], Rho has a particular role in cell body contraction. 
As shown in Fig. 5F, 0.1 M LPA caused only a marginal effect on the level of active 
GTP-RhoA. However, the higher doses of LPA (up to 10 M) increased the level of 
active GTP-RhoA (Fig. 5F), which was consistent with the result shown in Fig. 5C of 
the Y-27632 treatment on cells stimulated by a low dose of LPA (0.1 M), and may 
cause increased cytoskeletal contraction in the cells. Interestingly, this dose-range of 
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LPA (0.1 to 10 M) coincided with the inhibitory phase of the bell-shaped 
dose-response profile of LPA actions upon cell migration (Fig. 5A). Total RhoA levels 
were not affected by the LPA treatment and appeared to be constant.  
Utilising RNA interference technology, we then ablated the expression of LPA1 
receptor, which was predominantly expressed in ATDC5 cells (Fig. 3). Transfection of 
LPA1 siRNA selectively reduced the expression of LPA1 within 24 h as shown by 
RT-PCR analysis (Fig. 6A). The level of LPA1 transcripts was also evaluated by northern 
blot analysis and found to be less than 25% compared with that of control cells (data not 
shown). As shown in Fig. 6B, knockdown of LPA1 expression markedly impaired the 
migration of cells toward LPA (Fig. 6B), indicating that LPA1 receptor signaling is 
critically important for LPA-induced migration of ATDC5 cells.  
The LPA receptor antagonist Ki16425 suppresses the serum-induced migration of 
ATDC5 chondroprogenitor cells 
Serum contains LPA at levels of around 1-5 M, in addition to various related factors 
[44,45]. Fetal bovine serum is required for the maintenance of ATDC5 
chondroprogenitor cells, which are cultured in medium containing 5% FBS under 
standard conditions. To elucidate a role for serum LPA in the regulation of ATDC5 cells, 
we examined the effects of the LPA receptor antagonist Ki16425 upon these cultures. 
ATDC5 cells grown in culture medium containing 5% FBS showed a remarkable 
increase (132-fold over basal) in chemotactic migration, but LPA (0.1 M) treatment 
resulted in 65-fold increase in these levels (Fig. 7A). In addition, serum growth factors 
such as PDGF-BB (25 ng/ml; 4-fold increase) and IGF-I (100 ng/ml; 10-fold increase) 
were also capable of stimulating the migration of ATDC5 cells, whilst FGF2 (20 ng/ml) 
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did not show this capacity (Fig. 7B). Although 3 M Ki16425 completely suppressed 
LPA-induced migration (Figs. 5D and 7A), it did not affect the action of IGF-I or of 
PDGF-BB (Fig. 7B). About 70% of the FBS-stimulated increase of migration was found 
to be Ki16425-sensitive (Fig. 7A), suggesting that LPA is primarily responsible for the 
FBS-induced migration of these cells. IGF-I and/or PDGF in serum may thus account 
for the residual Ki16425-insensitive activity (about 30% of the activity in FBS).  
LPA receptor antagonist Ki16425 suppresses chondrogenic differentiation of ATDC5 
cells 
When cultured in 5% FBS in the presence of 10 g/ml insulin, ATDC5 cells undergo 
chondrogenic differentiation through the condensation stage after confluence (usually 
from day 3 to day 6 of culture under standard conditions) to form cartilage nodules that 
are rich in Alcian blue-positive cartilaginous extracellular matrix [29,46]. In the present 
study, we assessed the contribution of LPA in serum to chondrogenic differentiation of 
ATDC5 cells cultured in DMEM/F12 medium containing 5% FBS and ITS by adding 
Ki16425 from day 3, since serum-free chondrogenic culture of ATDC5 cells is not 
possible so far. On day 17, the cultures were fixed and stained with Alcian blue. As 
shown in Figs. 8A and 8B, Ki16425 markedly prevented the formation of Alcian 
blue-positive cartilage nodules at a dose of 0.1 M or higher. The level of type II 
collagen transcripts in cells cultured in the presence or absence of 3 M Ki16425 was 
determined on day 14 (Fig. 8C), whilst the levels of type X collagen transcripts were 
determined on day 21 of culture (Fig. 8C). Thus, the Ki16425-treated ATDC5 cells 
expressed a markedly lower level of type II and type X collagen transcripts compared 
with untreated cells in control culture, indicating that Ki16425 exerts inhibitory effects 
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on the progression of differentiation of ATDC5 cells.  
In summary therefore, our current findings demonstrate that LPA plays a role 
in the behaviors of ATDC5 chondroprogenitor cells. In the course of the present study, 
Jeon et al. have also reported that LPA stimulates the differentiation of human adipose 
tissue-derived mesenchymal stem cells to myofibroblastic-like cells [47]. Their findings 
are compatible with the notion that LPA affects behaviors of tissue stem/progenitor cells. 
Our present study suggests a possibility that LPA plays an important role in the 




The authors are grateful to Prof. Junken Aoki (Graduate School of Pharmaceutical 
Sciences, Tohoku University) and Prof. Yoh Takuwa (Kanazawa University Graduate 
School of Medicine) for their helpful advice. This work was supported in part by 
Grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology 
of Japan (Y.H.).  
 22 
References 
1. Cancedda R, Descalzi Cancedda F, Castagnola P (1995) Chondrocyte differentiation. 
Int Rev Cytol 159:265-358 
2. Hall BK, Miyake T (2000) All for one and one for all: condensations and the 
initiation of skeletal development. Bioessays 22:138-147 
3. Kronenberg HM (2003) Developmental regulation of the growth plate. Nature 
423:332-336 
4. Mills GB, Moolenaar WH (2003) The emerging role of lysophosphatidic acid in 
cancer. Nat Rev Cancer 3:582-591 
5. Alvarez SE, Milstien S, Spiegel S (2007) Autocrine and paracrine roles of 
sphingosine-1-phosphate. Trends Endocrinol Metab 18:300-307 
6. Bachner D, Ahrens M, Betat N, Schroder D, Gross G (1999) Developmental 
expression analysis of murine autotaxin (ATX). Mech Dev 84:121-125 
7. Ohuchi H, Hayashibara Y, Matsuda H, Onoi M, Mitsumori M, Tanaka M, Aoki J, 
Arai H, Noji S (2007) Diversified expression patterns of autotaxin, a gene for 
phospholipid-generating enzyme during mouse and chicken development. Dev Dyn 
236:1134-1143 
8. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills 
GB, Inoue K, Aoki J, Arai H (2002) Autotaxin has lysophospholipase D activity 
leading to tumor cell growth and motility by lysophosphatidic acid production. J 
Cell Biol 158:227-233 
9. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K 
(2002) Identification of human plasma lysophospholipase D, a lysophosphatidic 
 23 
acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol 
Chem 277:39436-39442 
10. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, 
Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, 
Jonkers J (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood 
vessel formation during development. Mol Cell Biol 26:5015-5022 
11. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki 
J, Arai H (2006) Autotaxin stabilizes blood vessels and is required for embryonic 
vasculature by producing lysophosphatidic acid. J Biol Chem 281:25822-25830 
12. Pyne S, Pyne N (2000) Sphingosine 1-phosphate signalling via the endothelial 
differentiation gene family of G-protein-coupled receptors. Pharmacol Ther 
88:115-131 
13. Tigyi G, Parrill AL (2003) Molecular mechanisms of lysophosphatidic acid action. 
Prog Lipid Res 42:498-526 
14. Contos JJ, Chun J (2000) Genomic characterization of the lysophosphatidic acid 
receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a 
previously characterized cDNA. Genomics 64:155-169 
15.Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. 
Nat Rev Mol Cell Biol 4:397-407 
16. Noguchi K, Ishii S, Shimizu T (2003) Identification of p2y9/GPR23 as a novel G 
protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg 
family. J Biol Chem 278:25600-25606 
17. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S, Owman C, 
Sillard R, Leeb-Lundberg LM, Olde B (2006) Lysophosphatidic acid binds to and 
 24 
activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal 
lymphocytes. J Pharmacol Exp Ther 318:619-628 
18. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J (2006) GPR92 as a new G12/13- 
and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol 
Chem 281:23589-23597 
19. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N (2007) The orphan GPCR GPR87 
was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem 
Biophys Res Commun 363:861-866 
20. Pasternack SM, von Kugelgen I, Aboud KA, Lee YA, Ruschendorf F, Voss K, 
Hillmer AM, Molderings GJ, Franz T, Ramirez A, Nurnberg P, Nothen MM, Betz 
RC (2008) G protein-coupled receptor P2Y5 and its ligand LPA are involved in 
maintenance of human hair growth. Nat Genet 40:329-334 
21. Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y, Taguchi R, 
Shimizu T, Ishii S (2009) Identification and characterization of a novel 
lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 284:17731-17741 
22. Murakami M, Shiraishi A, Tabata K, Fujita N (2008) Identification of the orphan 
GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid 
receptor. Biochem Biophys Res Commun 371:707-712 
23. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J (2000) Requirement for the 
lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl 
Acad Sci U S A 97:13384-13389 
24. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, 
Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL (2000) Edg-1, the G 
protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular 
 25 
maturation. J Clin Invest 106:951-961 
25. Chae SS, Paik JH, Allende ML, Proia RL, Hla T (2004) Regulation of limb 
development by the sphingosine 1-phosphate receptor S1p1/EDG-1 occurs via the 
hypoxia/VEGF axis. Dev Biol 268:441-447 
26. Kim MK, Lee HY, Park KS, Shin EH, Jo SH, Yun J, Lee SW, Yoo YH, Lee YS, 
Baek SH, Bae YS (2005) Lysophosphatidic acid stimulates cell proliferation in rat 
chondrocytes. Biochem Pharmacol 70:1764-1771 
27. Kim KW, Ha KY, Lee JS, Nam SW, Woo YK, Lim TH, An HS (2009) Notochordal 
cells stimulate migration of cartilage end plate chondrocytes of the intervertebral 
disc in in vitro cell migration assays. Spine J 9:323-329 
28. Facchini A, Borzi RM, Flamigni F (2005) Induction of ornithine decarboxylase in 
T/C-28a2 chondrocytes by lysophosphatidic acid: signaling pathway and inhibition 
of cell proliferation. FEBS Lett 579:2919-2925 
29. Shukunami C, Shigeno C, Atsumi T, Ishizeki K, Suzuki F, Hiraki Y (1996) 
Chondrogenic differentiation of clonal mouse embryonic cell line ATDC5 in vitro: 
differentiation-dependent gene expression of parathyroid hormone 
(PTH)/PTH-related peptide receptor. J Cell Biol 133:457-468 
30. Shukunami C, Ishizeki K, Atsumi T, Ohta Y, Suzuki F, Hiraki Y (1997) Cellular 
hypertrophy and calcification of embryonal carcinoma-derived chondrogenic cell 
line ATDC5 in vitro. J Bone Miner Res 12:1174-1188 
31. Atsumi T, Miwa Y, Kimata K, Ikawa Y (1990) A chondrogenic cell line derived 
from a differentiating culture of AT805 teratocarcinoma cells. Cell Differ Dev 
30:109-116 
32. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid 
 26 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159 
33. Kimura T, Mattei M-G, Stevens JW, Goldring MB, Ninomiya Y, Olsen BR (1989) 
Molecular cloning of rat and human type IX collagen cDNA and localization of the 
1(IX) gene on the human chromosome 6. Eur J Biochem 179:71-78 
34. Apte SS, Seldin MF, Hayashi M, Olsen BR (1992) Cloning of the human and mouse 
type X collagen genes and mapping of the mouse type X collagen gene to 
chromosome 10. Eur J Biochem 206:217-224  
35. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, 
Watanabe M, Chun J, Arai H (2004) Lysophosphatidic acid and autotaxin stimulate 
cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 
279:17634-17639 
36. Barrionuevo F, Taketo MM, Scherer G, Kispert A (2006) Sox9 is required for 
notochord maintenance in mice. Dev Biol 295:128-140 
37. Deutsch U, Dressler GR, Gruss P (1988) Pax 1, a member of a paired box 
homologous murine gene family, is expressed in segmented structures during 
development. Cell 53:617-625 
38. Contos JJ, Ishii I, Chun J (2000) Lysophosphatidic acid receptors. Mol Pharmacol 
58:1188-1196 
39. Zhang G, Contos JJ, Weiner JA, Fukushima N, Chun J (1999) Comparative analysis 
of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. 
Gene 227:89-99 
40. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E et al. (2003) Ki16425, a 
subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol 
Pharmacol 64:994-1005 
 27 
41. Lee MJ, Jeon ES, Lee JS, Cho M, Suh DS, Chang CL, Kim JH (2008) 
Lysophosphatidic acid in malignant ascites stimulates migration of human 
mesenchymal stem cells. J Cell Biochem 104:499-510 
42. Ridley AJ (2001) Rho GTPases and cell migration. J Cell Sci 114:2713-2722 
43. Raftopoulou M, Hall A (2004) Cell migration: Rho GTPases lead the way. Dev Biol 
265:23-32 
44. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH (1993) The bioactive 
phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 
291:677-680 
45. Sano T, Baker D, Virag T, Wada A, Yatomi Y, Kobayashi T, Igarashi Y, Tigyi G 
(2002) Multiple mechanisms linked to platelet activation result in lysophosphatidic 
acid and sphingosine 1-phosphate generation in blood. J Biol Chem 
277:21197-21206 
46. Shukunami C, Akiyama H, Nakamura T, Hiraki Y (2000) Requirement of autocrine 
signaling by bone morphogenetic protein-4 for chondrogenic differentiation of 
ATDC5 cells. FEBS Lett 469:83-87 
47. Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M, Suh DS, Yoon MS, Chang 
CL, Jung JS, Kim JH (2008) Cancer-derived lysophosphatidic acid stimulates 





FIG 1.  The expression pattern of LPA1 in E10.5 mouse embryos.  In situ hybridization 
was carried out with type II collagen antisense (A; Col II AS), Sox9 antisense (C; Sox9 
AS), Pax1 antisense (D; Pax1 AS), LPA1 antisense (E; LPA1 AS), ATX antisense (F; 
ATX AS), LPA1 sense (G; LPA1 S), and ATX sense (H; ATX S) riboprobes and the 
semi-serial section was stained with hematoxylin-eosin (B, HE). Transverse sections of 
an E10.5 mouse embryo were made at thoracic levels. Arrows in panel A, C, and E 
indicate the cartilaginous elements of vertebrae such as neural arch and rib. Dotted 
circles in panel D and E indicate Pax1-positive regions. drg; dorsal root ganglia, nt; 
neural tube, n; notochord, da; dorsal aorta. Bars, 100 m. 
 
FIG. 2.  The expression pattern of LPA1 in E11.5 mouse embryos.  In situ hybridization 
was carried out with LPA1 antisense (A; LPA1 AS), LPA1 sense (B; LPA1 S) and type II 
collagen antisense (C; Col II AS) riboprobes and semi-serial sagittal sections of an 
E11.5 mouse embryo. (D) A semi-serial section stained with hematoxylin-eosin (HE). 
(E-G) Magnified views of the boxed areas in e, f, and g, respectively. In each panel, the 
anterior side is on the right, and posterior is on the left. The arrowheads in E-G indicate 
the regions expressing LPA1 transcripts. Bars, 1.25 mm in A-D; 200 m in E-G. 
 
FIG. 3.  Expression of lysophospholipid receptors in ATDC5 cells and their temporal 
changes during chondrogenic differentiation.  Total RNA (15 g) isolated from ATDC5 
cells on the indicated day of culture was subjected to northern blot analysis with probes 
for LPA receptors (LPA1-3) and S1P receptors (S1P1-3). The same blot was also 
hybridized with probes for type II collagen (Col II) and type X collagen (Col X). 
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Aliquots of total RNA (15 g) isolated from testis, lung, kidney, and rib cartilage were 
also subjected to northern blot analysis as a positive control for the expression of LPA1 
(testis and lung), LPA2-3 (testis and kidney) or S1P1-3 (lung). The positions of 28S and 
18S ribosomal RNAs are indicated. The bottom panels show ethidium bromide-stained 
gels. Relative expression levels of LPA1 were determined by densitometric analysis and 
were normalized to the level on day 3. The relative levels were 1.0 on day 3, 1.2 on day 
7, 0.7 on day 14, 0.7 on day 17, 1.0 on day 26, and 0.9 on day 42. 
 
FIG. 4.  Effects of LPA and S1P on the growth of undifferentiated ATDC5 
chondroprogenitor cells in confluent cultures.  (A, B) The rate of DNA synthesis was 
assessed by BrdU incorporation. Cells were grown to confluence in 96-multiwell plates 
for three days in DMEM/F12 containing 5% FBS and ITS. The cells were then 
incubated with DMEM/F12 containing 0.1% BSA in the absence (□) or presence (■) 
of 100 ng/ml PTX for 24 h, treated with the indicated concentrations of LPA (A) or S1P 
(B) for an additional 24 h, and labeled with 1 nmol/ml BrdU for the last 4 h. The 
incorporation of BrdU into DNA was then determined. The values shown are the mean 
± SD of triplicate assays. Two independent experiments were carried out and gave 
similar results. (C) Cells were plated and grown in 12-multiwell plates to confluence in 
DMEM/F12 containing 5% FBS. The cells were then preincubated with DMEM/F12 
containing 0.3% FBS for 24 h. The medium was then replaced by the same medium 
with test samples. After incubation for 36 h, cells were counted with a hemocytometer 
after trypsinization. In the control wells treated with vehicle alone, the cell number was 
16.2 ± 2.0 × 10
4
 cells/well (100 ± 12%). The values shown are the mean ± SD of 
triplicate assays. (D, E) Activation of the ERK1/2 signaling in cells treated with LPA. 
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Cells were grown to confluence in 12-multiwell plates, and were preincubated in 
DMEM/F12 containing 0.1% BSA for 6 h. In some experiments, the cells were 
preincubated with 100 ng/ml PTX for the last 4 h. Cells were then incubated with 0.1 
 LPA for the indicated time in (D) or with various concentration of LPA for 5 min in 
the presence and absence of PTX or Ki16425 in (E). Phosphorylated ERK1/2 
(p-ERK1/2) and total ERK1/2 were visualized by western blotting.  
 
FIG. 5.  Effects of LPA and S1P on the migration of undifferentiated ATDC5 
chondroprogenitor cells.  (A) Cells were plated at 5 × 10
4
 cells/well on the top well of a 
migration chamber coated with type I collagen, and then allowed to migrate for 4 h 
toward the bottom well containing various concentrations of LPA (□) or S1P (■) in 
DMEM/F12 containing 0.1% BSA and ITS. The numbers of migrated cells shown are 
the mean ± SD of triplicate assays. (B) Cells were pre-incubated in DMEM/F12 
containing 0.1% BSA and ITS in the absence (-) or presence (+) of PTX (100 ng/ml) for 
4 h before harvesting. The transwell migration of cells was determined in the absence 
(-) or presence (+) of 0.1 M LPA in the bottom well. Values shown are the means ± SD 
of quintuplicate assays. (C) Cells were resuspended in DMEM/F12 containing 0.1% 
BSA and ITS, then preincubated with selective inhibitors of PI3K (LY294002; LY, 20 
M), MEK1/2 (U0126; U, 10 M), and ROCK (Y-27632; Y, 10 M) for 30 min prior to 
seeding onto transwells. The transwell migration of cells was performed in the absence 
(-) or presence (+) of 0.1 M LPA in the bottom well. Values shown are the means ± SD 
of quintuplicate assays. (D) The inhibition of LPA-stimulated migration of cells by 
Ki16425. The transwell migration of cells toward 0.1 M LPA was determined in the 
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presence of various concentrations of Ki16425 in the top well. Values shown are the 
mean ± SD of triplicate assays. (E) Cells grown on glass chamber slides were 
pre-incubated for 6 h in DMEM/F12, and stimulated without (control) or with 0.1 M 
LPA in the absence or presence of 3 M Ki16425, or with 10 M LPA for 30 min. Cells 
were then fixed, permeabilized and stained for actin fibers (red) and focal adhesion 
(green) using phalloidin and an antibody to paxillin, respectively. Bars, 20m. (F) 
Activation of RhoA by LPA. Cells were serum-starved in DMEM/F12 containing 0.1% 
BSA for 6 h and then stimulated with LPA for 2 min. Cell lysates were analyzed for 
active RhoA (GTP-RhoA) by an affinity pull-down assay using Rhotekin-RBD agarose 
beads. Bound proteins were then subjected to western blot analysis using anti-RhoA 
mouse monoclonal antibody. Aliquots of cell lysates were subjected to western blotting 
with the anti-RhoA antibody for the assessment of total RhoA levels in cells, which 
remained constant with or without LPA treatments.  
 
FIG. 6.  Role of LPA1 signaling in the LPA-induced migration of ATDC5 
chondroprogenitor cells.  (A) Knockdown of LPA1 expression by siRNA. Cells were 
transfected with non-targeting siRNA (ctrl) or LPA1 siRNA by electroporation. Total 
RNA was extracted from the cells 24 h after transfection, and the expression levels of 
LPA1 (30 cycles), LPA2 (35 cycles), LPA3 (35 cycles), and GAPDH (30 cycles) 
transcripts were analyzed by RT-PCR. GAPDH was used as an internal control. (B) 
Cells were transfected with non-targeting (control) siRNA (□) or LPA1 siRNA (■). 24 
h after transfection, cells were harvested, resuspended in DMEM/F12 containing 0.1% 
BSA and ITS. The transwell migration of cells was performed in the absence (-) or 
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presence (+) of 0.1 M LPA in the bottom well. Values shown are the means ± SD of 
quintuplicate assays. 
 
FIG. 7.  Effects of different growth factors and FBS on the migration of undifferentiated 
ATDC5 chondroprogenitor cells.  (A) The transwell migration of cells toward 5% FBS 
or 0.1 M LPA was assessed in the absence (□) or presence (■) of 3 M Ki16425 in 
the top well. Values are the means ± SD of quintuplicate assays. (B) The transwell 
migration of cells toward 100 ng/ml IGF-I, 25 ng/ml PDGF-BB or 20 ng/ml FGF2 was 
assessed in the absence or presence of 3 M Ki16425 in the top well. Values are the 
means ± SD of triplicate assays. (C) Transwell migration of cells toward 25 ng/ml 
PDGF-BB was determined in the presence of various concentrations of LPA (□) or S1P 
(■) in the bottom well. Values are the means ± SD of triplicate assays.  
 
Fig. 8.  Effects of the LPA receptor antagonist Ki16425 on chondrogenic differentiation 
of ATDC5 cells.  (A) Cells were plated at 2 × 10
4
 cells per well in 24-multiwell plates 
and allowed to differentiate by culturing for 17 days in DMEM/F12 medium containing 
5% FBS and ITS. From day 3, cells were cultured in the same medium containing 
different concentrations (M) of Ki16425. Cells were fixed on day 17 and stained with 
Alcian blue. The figure represents one of three independent experiments that gave 
similar results. DMSO (at a final concentration of 0.1%) that was used as a solvent for 
Ki16425 had no significant effects alone on the differentiation of ATDC5 cells. (B) 
Quantitative analysis of Alcian blue-positive nodules formed in the ATDC5 cell cultures 
shown in panel A. Images of the wells stained by Alcian blue were taken and the stained 
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area in each well was analyzed using NIH image. Values are expressed as a percentage 
of the total stained area of the well cultured with vehicle alone in the absence of 
Ki16425 (denoted as 0 M), and are means ± SD of quintuple assays. (C) Effects of 
Ki16425 on the expression of type II and type X collagen in ATDC5 cells. Cells were 
plated at 6 × 10
4
 cells/well in 6-multiwell plates and allowed to differentiate in 
DMEM/F12 containing 5% FBS and ITS. After the culture reached confluence on day 3, 
cells were cultured in the absence or presence of 3 M Ki16425 in DMEM/F12 
containing 5% FBS and ITS. Total RNA (5 g) isolated from ATDC5 cells on day 14 
and day 21 was subjected to northern blot analysis using probes for type II collagen 
(Col II) and type X collagen (Col X), respectively. The positions of 28S and 18S 
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Table 1. List of primers used for RT-PCR 
 
Gene Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
LPA1 GAACACAGTGAGCAAGCTGG CATAGCAGAGTTGAACTCGGC 
LPA2 GCATGGCTCTTCAACACTCC AGTTCAAGGCCATCCTCACC 
LPA3 TATCTCCACACACCAGTGGC AGGTGAGGACGCTTAACAGC 
S1P1 CATCTGCTGCTTCATCATCC TAGTGCTTGTGGTAGAGCGG 
S1P2 GAACAGCAAGTTCCACTCAGC TATGCATGCCTCTCTCCAGG 
S1P3 GCGTGTTCCTTCTGATTGG AATAGGTGTGGCTGCAGAGC 
Table 1
